Bangladesh is a South Asian country with a homogeneous population. However, some difference
has been demonstrated in the distribution of liver disease in different parts of the country. Hepatitis E
remains the principal cause of acute hepatitis in Bangladesh, while chronic liver disease in Bangladesh,
including hepatocelullar carcinoma, is predominantly due to hepatitis B virus. Hepatitis B has been
extensively studied and characterized in Bangladesh, and some major clinical trials with HBV-related
antigens have also been conducted.
Rahman S, Mahtab MA, Foster G, Khan M, Karim MF, Solaiman S, Afroz S. Epidemiology of hepatitis B virus in Bangladeshi General Population. Hepato Bil Pancreat Dis Int 2008;7(6):595-600
Clinical use of liver biopsy for the diagnosis and management of inactive and asymptomatic hepatitis B virus carriers in Bangladesh. J Med Virol 2010;82(8):1350-1354
Biochemical, virological, immunological and histopathological features of 702 incidentally detected chronic hepatitis B virus carriers in Bangladesh. Digestion 2012;86(1):1-5
Genotypes of hepatitis B virus among chronically infected patients in a tertiary care hospital in Bangladesh. Indian J of Gastroenterol 2006;25(4):219-221
Pre-core/core Promoter mutant hepatitis B virus produces more severe histologic liver disease than wild type hepatitis B virus. Hungarian Med J 2007;1(1):41-46
Viral load speaks little about toll on liver. Hepato Bil Pancreat Dis Int 2007;6(4):223-226
Assessment of clinical utility of low and high normal alanine aminotransferase values in patients with chronic hepatitis B virus Infection at Bangladesh. Digestion 2010;83(1-2):60-64
Economic burden of chronic hepatitis B virus infection in Bangladesh. Hepatol Int 2012;6(1)(Suppl):129
Combination therapy with antiviral drugs and hepatitis B vaccine in incidentally-detected Epidemiology of Viral Hepatitis and Liver Diseases in Bangladesh Euroasian Journal of Hepato-Gastroenterology, January-June 2015;5(1):26-29 29 EJOHG and asymptomatic chronic hepatitis virus B carriers at Bangladesh. Viral Immunol 2010;23(3):335-338
Combination therapy of lamivudine and interferon alpha in pediatric patients with chronic hepatitis B at Bangladesh: a safe and effective therapeutic approach for pediatric CHB patients of developing countries. Int J Immunopathol Pharmacol 2010;23(2):659-664
Response to combination therapy with ‘shorter duration’ and ‘half dose’ pegylated interferon and entecavir in chronic hepatitis B in Bangladesh. J Hepatol 2012;2(56)(Suppl):65
Therapeutic potential of a novel therapeutic vaccine containing both hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) administered through mucosal and parental route in patients with chronic hepatitis B. Hepatology 2010;52(Suppl 4):538-539
Therapeutic potential of a combined hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis B. Hepatol Int 2013;7(4):981-989
Comparison of seroepidemiology of hepatitis C in blood donors between Bangladesh and Japan. Gastroenterol Jpn 1993;28(Suppl 5):28-31
Seroepidemiology of hepatitis viruses of chronic liver diseases in Bangladesh: high prevalence of HCV among blood donors and healthy persons. Hepatol Res 1997;7(2):113-120
Prevalence and risk factors of asymptomatic HCV infection in Bangladesh. J Clin Experiment Hepatol 2011;1(1):13-16
Prevalence and risk factors of hepatitis B and C virus infections in an impoverished urban community in Dhaka, Bangladesh. MC Infect Dis 2010;10(1):208
Seroprevalence of Hepatitis B, Hepatitis C, HIV Infections in blood donors of Khulna, Bangladesh. Mymensingh Med J 2010;19(4):515-519
Indication of determination of antibodies against hepatitis C and A viruses in the protocol for the care of young immigrants. Gac Sanit 2010;24(4):288-292
Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: the prevalence cannot necessarily be predicted from the prevalence in the country of origin. J Viral Hepat 2010;17(5):327-335
Prevalence and risk factors of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infections among drug addicts in Bangladesh. J Health Popul Nutr 2000;18(3):145-150
Prevalence of HBV and HCV among the multi-transfused beta thalassemic major patients in a day care centre of blood transfusion department of Mymensingh Medical College Hospital. Mymensingh Med J 2014;23(2):235-241
HCV in Pakistani: a systematic review of prevalence genotypes and risk factors. World J Gastroenterol 2009;15(45):5647-5653
Role of potash alum in hepatitis C virus transmission at barber’s shop. Virol J 2011 May 9;8:211
Genotypes of HCV in Bangladesh: Experience from a tertiary centre. Hungarian Med J 2008;2(4):577-581
Genotypes of HCV in Bangladesh: experience from a tertiary centre. J Gastroenterol Hepatol 2008;23(Suppl):27-28
Peginterferon α-2a and rivabirin in the treatment of chronic Hepatitis C. Mymensingh Med J 2014 Apr;23(2):335-340
Sustained virological response after treatment in patients with chronic hepatitis C infection—a 5-year follow-up. Bangladesh Med Res Counc Bull 2013;39(1):11-13
Epidemiological and molecular analyses of a non-seasonal outbreak of acute icteric hepatitis E in Bangladesh. J Med Virol 2013;85(8):1369-1376
HEV infection as an etiologic factor for acute hepatitis: experience from a tertiary hospital in bangladesh. J Health Popul Nutri 2009; 27(1):14-19
Hepatitis E virus is the leading cause of acute-on-chronic liver disease: Experience from a tertiary centre in Bangladesh. Hepat Bil Pancreat Dis Int 2009;8(1):50-52
Distribution of liver disease in Bangladesh: a cross country study. Euroasian J Hepato-Gastroenterol 2014;4(1):25-30
Hepatitis B virus related hepatocellular carcinoma is the predominant cause of liver cancer in Bangladesh. J Acute Dis 2013;1(1):35-37
Chronic liver disease is one of the leading causes of death in Bangladesh: experience by death audit from a tertiary hospital. Euroasian J Hepato-Gastroenterol 2014; 4(1):17-20.
